已传文件：photo/1768377739.png
hematologic malignancies (HM) are a large category of abnormal cell proliferation diseases originating from the lymphohematopoietic system, which can involve multiple tissues and organs. HM is mainly classified into three categories: leukemia, multiple myeloma (MM), and lymphoma. Although advancements in medical technology have improved the prognosis of many patients, there are still differences in their survival rates. Given the dynamic nature of HM and its increasing global burden, understanding its epidemiological trends is crucial for formulating effective public health strategies and evaluating the effectiveness of current medical interventions.
In November 2025, the research group of Sang Wei from the Affiliated Hospital of Xuzhou Medical University, in collaboration with the research group of CAI Guoqi from Anhui Medical University, Published an article titled "Global Burden of Hematologic Malignancies From 1990 to 2021 With Projections to 2030" in iNew Medicine: the article "A Systematic Analysis for the Global Burden of Disease Study 2021" This study aims to comprehensively analyze the epidemiological trends and global disease burden of HM from 1990 to 2021, and predict the trends up to 2030. Based on the data from the 2021 Global Burden of Disease (GBD) study, the authors analyzed four types of age-standardized indicators, including age-standardized morbidity (ASIR), prevalence (ASPR), mortality (ASMR), and disability-adjusted life rate (ASDR). The epidemiological trends of HM from 1990 to 2021 were systematically evaluated. Decomposition analysis was adopted to evaluate the contribution of determinants of the population level. An age-period-cohort (APC) model was established to predict the burden of HM. From 1990 to 2021, the global prevalence of HM increased significantly, from 2.34358 million cases to 5.39105 million cases. In 2021 age-standardized incidence rate of leukemia, multiple myeloma, Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) The ASIR rates are 5.6, 1.7, 0.8 and 7.1 per 100,000 people respectively. From 1990 to 2021, although the ASIR, age-standardized mortality rate (ASMR), and age-standardized disability-adjusted life rate (ASDR) of leukemia decreased, However, age-standardized prevalence (ASPR) has increased. Both the ASIR and ASPR of MM and NHL show an upward trend, among which the ASMR of MM has also increased. However, all the indicators of HL showed a downward trend. The peak incidence rates of leukemia, MM, HL and NHL in 2021 were respectively in the age groups of 0-4 years old, 25-34 years old, 65-74 years old and 70-74 years old. Decomposition analysis shows that population growth contributes the most to the increase of NHL ASDR. By 2030, ASDR of leukemia, HL and NHL is expected to decline, while ASDR of MM is expected to rise. The global burden of HM has undergone significant changes, and the trends of incidence and mortality of different types of HM vary.
Original link：https://onlinelibrary.wiley.com/doi/10.1002/inm3.70008
This chapter is not completed. You can go to:https://mp.weixin.qq.com/s/miFkLPR5H_v_cVnml75IoA
